Evaluation of Blood Protein O-GlcNAcylation Levels in Children
Key facts
- Who runs it
- Nantes University Hospital
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 240 people, planned
- Started
- 30 Jan 2025
- Expected to end
- 31 Jan 2036
- Type of study
- Observational, 2 groups
- Record updated
- 12 November 2026
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Age from 0 to 17 years at the time of sampling (including premature infants)
- Children coming to hospital for a blood sample to be taken as part of a pre-operative check-up, an allergy check-up or a check-up as part of a pathology other than sepsis
- Premature infants benefiting from a blood sample as part of their monitoring and management of prematurity
- Collection of umbilical cord blood
- Signed consent
- Age from 0 to 17 years at the time of sampling (including preterm infants)
- Children with suspected sepsis or diagnosed sepsis according to the 2016 definition
- Premature infants having blood drawn for suspected or diagnosed sepsis
- All responsible bacteria, viruses or fungi
- Signed bio-collection consent
Who cannot take part
- Children with an infection
- Children with autoimmune disease
- Children with metabolic disease
- Children with haematological diseases
- Children with a genetic disease
- Children with autoimmune disease
- Children with a metabolic disease
- Children with haematological diseases
- Children with a genetic disease
- Children with fever
- Children with an immune deficiency
- Unsigned consent
- Refusal by parents or child
- Septic group
- Children with an immune deficiency
- Unsigned bio-collection consent
- Refusal by parents or child
Other criteria
- Healthy group
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Stimulation of O-GlcNAcylation has been shown to be beneficial in several acute pathologies and different animal models, such as haemorrhagic and septic shock, and ischaemia-reperfusion (cerebral and cardiac). It could therefore be interesting to use this approach in children in order to limit the impact of various pathologies inducing SIRS, such as extracorporeal circulation for major surgery, septic shock or various traumas. The investigators demonstrated in 2 different animal models (endotoxemia by injection of Lipopolysaccharides and caecal puncture ligation model) with 3 different pharmacological molecules (Glucosamine, ThiametG and NButGT) that stimulation of O-GlcNAcylation was beneficial in the early phase of septic shock with a marked effect on cardiac function and survival. The investigators thus demonstrated that stimulation of O-GlcNAcylation was beneficial in young rats in septic shock. However, none of this work has yet been reproduced in humans, either children or adults.
The 2 groups in the trial
- Healthy group
children attending hospital and receiving a blood sample as part of their care during general paediatric consultations, anaesthesia or day hospital consultations. Children requiring a blood test as part of a medical indication in the first week of life / blood samples taken at birth from cord blood. A blood sample will be taken at inclusion during a blood test carried out in the care unit, and possibly if other blood samples are planned as part of the care, additional samples will be taken in a maximum of 6 tubes in 48 hours, i.e. for a total volume of 600 µl to 3 ml. The child's clinical data will be collected in his medical file.
- Septic shock
Children attending a paediatric emergency department for a severe infection requiring vascular filling, or a child admitted to an intensive care unit for sepsis or presenting with sepsis during hospitalisation. A blood sample will be taken at inclusion during a blood test carried out in the care unit and then at H3, H6, H12, H24 and H48, i.e. 6 times in 48 hours for a total volume of 600 µl to 3 ml for patients in septic shock. The child's clinical data will be collected in his medical file.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Blood Protein O-GlcNAcylation Levels in Children - CHANCE Study (Child Heart O-glcnAc Nantes)
- Record updated
- 12 November 2026